- Home
- VSTM vs TSHA Comparison
VSTM vs TSHA Comparison
Compare VSTM & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- TSHA
- Stock Information
- Founded
- VSTM 2010
- TSHA 2019
- Country
- VSTM United States
- TSHA United States
- Employees
- VSTM N/A
- TSHA N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- TSHA Health Care
- Exchange
- VSTM Nasdaq
- TSHA Nasdaq
- Market Cap
- VSTM 359.9M
- TSHA 397.8M
- IPO Year
- VSTM 2012
- TSHA 2020
- Fundamental
- Price
- VSTM $7.17
- TSHA $2.13
- Analyst Decision
- VSTM Strong Buy
- TSHA Strong Buy
- Analyst Count
- VSTM 9
- TSHA 8
- Target Price
- VSTM $13.63
- TSHA $6.63
- AVG Volume (30 Days)
- VSTM 1.4M
- TSHA 3.0M
- Earning Date
- VSTM 05-20-2025
- TSHA 05-16-2025
- Dividend Yield
- VSTM N/A
- TSHA N/A
- EPS Growth
- VSTM N/A
- TSHA N/A
- EPS
- VSTM N/A
- TSHA N/A
- Revenue
- VSTM $10,000,000.00
- TSHA $8,333,000.00
- Revenue This Year
- VSTM $7.68
- TSHA N/A
- Revenue Next Year
- VSTM $605.06
- TSHA N/A
- P/E Ratio
- VSTM N/A
- TSHA N/A
- Revenue Growth
- VSTM N/A
- TSHA N/A
- 52 Week Low
- VSTM $2.10
- TSHA $1.05
- 52 Week High
- VSTM $13.52
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- VSTM 57.92
- TSHA 58.69
- Support Level
- VSTM $6.35
- TSHA $1.85
- Resistance Level
- VSTM $8.00
- TSHA $2.28
- Average True Range (ATR)
- VSTM 0.67
- TSHA 0.26
- MACD
- VSTM 0.01
- TSHA 0.03
- Stochastic Oscillator
- VSTM 46.93
- TSHA 52.96
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.